+1 858-523-8231
Login | Register
menu
AA Blocks, Building Blocks, Catalysts, Inhibitors
Login | Register
31645-39-3,MFCD01705455
Catalog No.:AA000ZGV

31645-39-3 | Palifosfamide

Pack Size
Purity
Availability
Price(USD)
Quantity
  
10mg
≥95%
in stock  
$48.00   $33.00
- +
25mg
≥95%
in stock  
$105.00   $73.00
- +
50mg
≥95%
in stock  
$160.00   $112.00
- +
100mg
≥95%
in stock  
$252.00   $176.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA000ZGV
Chemical Name:
Palifosfamide
CAS Number:
31645-39-3
Molecular Formula:
C4H11Cl2N2O2P
Molecular Weight:
221.0221
MDL Number:
MFCD01705455
SMILES:
ClCCNP(=O)(NCCCl)O
NSC Number:
297900
Properties
Properties
 
Form:
Solid  
MP:
106-107℃  
Storage:
-20 ℃;  

Computed Properties
 
Complexity:
134  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0  
Defined Bond Stereocenter Count:
0  
Formal Charge:
0  
Heavy Atom Count:
11  
Hydrogen Bond Acceptor Count:
4  
Hydrogen Bond Donor Count:
3  
Isotope Atom Count:
0  
Rotatable Bond Count:
6  
Undefined Atom Stereocenter Count:
0  
Undefined Bond Stereocenter Count:
0  
XLogP3:
-0.4  

Downstream Synthesis Route
31645-39-3    39070-14-9   
(2-chloroethyl)((2-chloroethyl)amino(2-nitro-3-methylimidazol-4-yl)methoxyphosphoryl})amine 

[1]JournalofMedicinalChemistry,2008,vol.51,p.2412-2420

[2]Patent:WO2007/2931,2007,A2.Locationinpatent:Page/Pagecolumn76;124-125

[1]Actapoloniaepharmaceutica,2013,vol.70,p.481-487

[1]Actapoloniaepharmaceutica,2013,vol.70,p.481-487

Literature

Title: Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys.

Journal: Cancer chemotherapy and pharmacology 20120301

Title: Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin.

Journal: Anti-cancer drugs 20120201

Title: The effect of N-acetylcysteine on the antitumor activity of ifosfamide.

Journal: Canadian journal of physiology and pharmacology 20110501

Title: Ifosfamide metabolites CAA, 4-OH-Ifo and Ifo-mustard reduce apical phosphate transport by changing NaPi-IIa in OK cells.

Journal: Kidney international 20061101

Title: [Identification of glufosfamide metabolites in rats].

Journal: Yao xue xue bao = Acta pharmaceutica Sinica 20060601

Title: Comparative preclinical toxicology and pharmacology of isophosphoramide mustard, the active metabolite of ifosfamide.

Journal: Cancer chemotherapy and pharmacology 20050201

Title: 1,3- vs 1,5-intramolecular alkylation reactions in isophosphoramide and phosphoramide mustards.

Journal: Chemical research in toxicology 20040901

Title: Phosphate prodrugs of isophosphoramide mustard.

Journal: Acta poloniae pharmaceutica 20030101

Title: Isophosphoramide mustard analogues as prodrugs for anticancer gene-directed enzyme-prodrug therapy (GDEPT).

Journal: Acta biochimica Polonica 20020101

Title: Mechanisms of resistance against cyclophosphamide and ifosfamide: can they be overcome without sacrificing selectivity?

Journal: Cancer treatment and research 20020101

Title: Identification of new aqueous chemical degradation products of isophosphoramide mustard.

Journal: Journal of pharmaceutical and biomedical analysis 20010601

Title: Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma.

Journal: Lancet (London, England) 19800927

Title: Hingorani P, et al. Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma. Cancer Chemother Pharmacol. 2009 Sep;64(4):733-40.

Title: Jones B, et al. Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anticancer Drugs. 2012 Feb;23(2):173-84.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
Submit
SDS
Related Products of 31645-39-3
Building Blocks
More >
Historical Records
1803601-10-6

1803601-10-6

 60455-40-5

60455-40-5
Tags:31645-39-3 Molecular Formula|31645-39-3 MDL|31645-39-3 SMILES|31645-39-3 Palifosfamide
Catalog No.: AA000ZGV
31645-39-3,MFCD01705455
31645-39-3 | Palifosfamide
Pack Size： 10mg
Purity： ≥95%
in stock
$48.00 $33.00
Pack Size： 25mg
Purity： ≥95%
in stock
$105.00 $73.00
Pack Size： 50mg
Purity： ≥95%
in stock
$160.00 $112.00
Pack Size： 100mg
Purity： ≥95%
in stock
$252.00 $176.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA000ZGV
Chemical Name: Palifosfamide
CAS Number: 31645-39-3
Molecular Formula: C4H11Cl2N2O2P
Molecular Weight: 221.0221
MDL Number: MFCD01705455
SMILES: ClCCNP(=O)(NCCCl)O
NSC Number: 297900
Properties
Form: Solid  
MP: 106-107℃  
Storage: -20 ℃;  
Complexity: 134  
Covalently-Bonded Unit Count: 1  
Defined Atom Stereocenter Count: 0  
Defined Bond Stereocenter Count: 0  
Formal Charge: 0  
Heavy Atom Count: 11  
Hydrogen Bond Acceptor Count: 4  
Hydrogen Bond Donor Count: 3  
Isotope Atom Count: 0  
Rotatable Bond Count: 6  
Undefined Atom Stereocenter Count: 0  
Undefined Bond Stereocenter Count: 0  
XLogP3: -0.4  
Downstream Synthesis Route
31645-39-3    39070-14-9   
(2-chloroethyl)((2-chloroethyl)amino(2-nitro-3-methylimidazol-4-yl)methoxyphosphoryl})amine 

[1]JournalofMedicinalChemistry,2008,vol.51,p.2412-2420

[2]Patent:WO2007/2931,2007,A2.Locationinpatent:Page/Pagecolumn76;124-125

625-56-9    31645-39-3    1605307-59-2 

[1]Actapoloniaepharmaceutica,2013,vol.70,p.481-487

5335-05-7    31645-39-3    1605307-14-9 

[1]Actapoloniaepharmaceutica,2013,vol.70,p.481-487

Literature fold

Title: Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys.

Journal: Cancer chemotherapy and pharmacology20120301

Title: Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin.

Journal: Anti-cancer drugs20120201

Title: The effect of N-acetylcysteine on the antitumor activity of ifosfamide.

Journal: Canadian journal of physiology and pharmacology20110501

Title: Ifosfamide metabolites CAA, 4-OH-Ifo and Ifo-mustard reduce apical phosphate transport by changing NaPi-IIa in OK cells.

Journal: Kidney international20061101

Title: [Identification of glufosfamide metabolites in rats].

Journal: Yao xue xue bao = Acta pharmaceutica Sinica20060601

Title: Comparative preclinical toxicology and pharmacology of isophosphoramide mustard, the active metabolite of ifosfamide.

Journal: Cancer chemotherapy and pharmacology20050201

Title: 1,3- vs 1,5-intramolecular alkylation reactions in isophosphoramide and phosphoramide mustards.

Journal: Chemical research in toxicology20040901

Title: Phosphate prodrugs of isophosphoramide mustard.

Journal: Acta poloniae pharmaceutica20030101

Title: Isophosphoramide mustard analogues as prodrugs for anticancer gene-directed enzyme-prodrug therapy (GDEPT).

Journal: Acta biochimica Polonica20020101

Title: Mechanisms of resistance against cyclophosphamide and ifosfamide: can they be overcome without sacrificing selectivity?

Journal: Cancer treatment and research20020101

Title: Identification of new aqueous chemical degradation products of isophosphoramide mustard.

Journal: Journal of pharmaceutical and biomedical analysis20010601

Title: Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma.

Journal: Lancet (London, England)19800927

Title: Hingorani P, et al. Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma. Cancer Chemother Pharmacol. 2009 Sep;64(4):733-40.

Title: Jones B, et al. Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anticancer Drugs. 2012 Feb;23(2):173-84.

Related Products of of 31645-39-3
Building Blocks More >
131819-23-3
131819-23-3
Trans-4-(3,4,5-trifluorophenyl)-trans-4'-propylbicyclohexane
AA000ZP7 | MFCD09838998
13205-49-7
13205-49-7
Benzoic acid, 4-(ethylthio)-
AA00101J | MFCD00002556
132213-07-1
132213-07-1
Imidazo[1,2-a]pyridin-6-ylmethanol
AA0010BN | MFCD00077049
132489-69-1
132489-69-1
O-(2-Acetamido-2-deoxy-d-glucopyranosylidene)amino n-phenyl carbamate
AA0010NN | MFCD00145022
132740-61-5
132740-61-5
4-Piperidineethanamine, 1-cyclopentyl-
AA001102 | MFCD08059857
132927-08-3
132927-08-3
2-Methoxy-4-(trifluoromethyl)benzonitrile
AA0011BX | MFCD02101784
1363381-27-4
1363381-27-4
1-(Boc-amino)-3-fluorocyclobutanecarboxylic acid
AA0011LY | MFCD22566202
13649-88-2
13649-88-2
(6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-8b-Acetyl-7-hydroxy-6a,8a,10-trimethyl-6a,6b,7,8,8a,8b,11a,12,12a,12b-decahydro-1H-naphtho[2',1':4,5]indeno[1,2-d]oxazol-4(2H)-one
AA0011UF | MFCD09037388
136539-01-0
136539-01-0
Ethyl 2-amino-5-chlorothiazole-4-carboxylate
AA0011YU | MFCD08704623
13678-68-7
13678-68-7
Ethanethioic acid, S-(2-furanylmethyl) ester
AA0012A2 | MFCD00010083
Historical Records
1803601-10-6
1803601-10-6
60455-40-5
60455-40-5
Submit
© 2017 AA BLOCKS, INC. All rights reserved.